Glaxo SmithKline announces start of Phase lll programme for mepolizumab in severe refractory asthma
Posted by
www.biotecnika.org
Asthma is a chronic condition that ultimately results in the inflammation of the air passages, making it extremely difficult to breath. Asthma can be life threatening, especially when serious cases are not effectively managed by use of an inhaler or medication.
Subscribe to:
Post Comments (Atom)
Post a Comment